Novacyt Posts Flat Revenues for H1 2018

Aug 02, 2018

|

NEW YORK (GenomeWeb) — Novacyt today reported revenues of €7 million ($8.1 million) for the first half of 2018, unchanged from the year-ago period as gains in the company's Lab21 protein diagnostics and Primerdesign molecular diagnostics units were offset by weak demand for its Novaprep cytology products.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Novacyt Posts Flat Revenues for H1 2018

To read the full story....

Breaking News

Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

ASU Team Wins $6M in Government Funding to Develop Rapid Saliva Testing System for Coronavirus

Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

What's Popular?

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

United Airlines Launches COVID-19 Testing Program for Travelers to Hawaii

ASU Team Wins $6M in Government Funding to Develop Rapid Saliva Testing System for Coronavirus

Abacus Diagnostica Readying Multiplex RT-PCR Test for SARS-CoV-2, Flu, RSV

Sponsorships